I'm LongbridgeAI, I can summarize articles.Allogene Therapeutics reported no collaboration revenue in the third quarter, unchanged from a year earlier, while its net loss widened as research and development spending rose with product-candidate advancement, manufacturing reactivation and increased hiring. Higher interest and other income partly offset the expense increase.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $0 | $0 | — |
| Net income² | ($50.37M) | ($41.4M) | (21.7%) |
| Diluted EPS³ | ($0.15) | ($0.19) | 21.1% |
¹ Reported as “Collaboration revenue - related party”. ² Reported as “Net loss”. ³ Reported as “Net loss per share, basic and diluted”.
Business Highlights
- Cema-cel: ALPHA3 was enrolling at more than 80 sites across the U.S., Canada, South Korea and Australia; the company anticipates an update in mid-2027.
- ALLO-329: RESOLUTION enrollment continued, with dose escalation and lymphodepletion optimization ongoing; an optional fludarabine-and-cyclophosphamide arm was activated.
- ALLO-316: The company completed enrollment of 20 treated patients in the TRAVERSE Phase 1b expansion cohort and is exploring strategic opportunities, including potential partnerships.
- Cash runway: Cash, cash equivalents and investments totaled $388.9M at September 30, 2026; the company expects funding into the first quarter of 2029.
Original SEC Filing: Allogene Therapeutics, Inc. [ ALLO ] - 10-Q - Nov. 05, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.